Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
2023年10月23日 - 9:12PM
Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”),
a global clinical-stage biotechnology company focused on innovative
oncology drugs, and Nucleai, a pathology-based AI-powered biomarker
discovery and diagnostics company, is pleased to announce today the
receipt of the ESMO 2023 Best Poster Award for the Sunday, October
22, 2023 poster session with the presentation of the study
“Utilizing H&E Images and Digital Pathology to Predict Response
to Buparlisib in SCCHN”. The study assessed a novel methodology for
identifying recurrent or metastatic squamous cell carcinoma of the
head and neck (SCCHN) patients that are likely to benefit from
combination Buparlisib + paclitaxel treatment. The focus is to
examine AI-based structuring and analyze H&E images to identify
spatial features associated with clinical outcomes.
"Identifying potential candidates for Buparlisib + paclitaxel
therapy among metastatic SCCHN patients is an important step to
provide safer, more effective treatments, in order to realize
positive health related outcomes, in a timely manner and to
ultimately save lives. We are extremely pleased the study was
recognized for its quality and success,” said Dr. Lars Birgerson,
President & CMO of Adlai Nortye.
“We are excited to bring novel spatial biomarkers to the
forefront of drug research and development, and look forward to
further validating these findings in partnership with Adlai
Nortye,” said Oscar Puig, VP Translational Medicine and Diagnostics
at Nucleai.
The poster, #869P, was presented at the Head and Neck Cancers
poster session on Sunday, October 22, 2023. The Best Poster Award
was given at the conclusion of the Sunday Poster Session.
About Buparlisib
(AN2025)Buparlisib (AN2025) is an oral pan-PI3K inhibitor
that targets all class I PI3K isoforms and is active in both
hematologic malignancies and solid tumors. It is currently under
development for metastatic SCCHN in the ongoing global Phase III
BURAN study (NCT04338399).
About the BURAN studyThe BURAN
study is a randomized, open-label, multicenter phase III study to
assess the treatment effect of once-daily buparlisib in combination
with weekly paclitaxel compared to weekly paclitaxel alone in
patients with recurrent or static head and neck squamous cell
carcinoma (HNSCC) that have progressed after prior
anti-PD-1/anti-PD-L1 monotherapy; prior anti-PD-1/anti-PD-L1
therapy in combination with platinum-d therapy; or after sequential
treatment of anti-PD-1/anti-PD-L1 therapy, either prior to or post,
platinum-based therapy. About Adlai Nortye
(ANL)Adlai Nortye is a global clinical-stage biotechnology
company focused on innovative oncology drugs, with its R&D and
global clinical operation centers in both China and the U.S. With a
strategic emphasis on oncology, the Company has built a global
pipeline through collaborations and internal discovery with six
drug candidates in development. Currently, three of them are being
investigated in multiple clinical trials, including (i) Buparlisib
(AN2025) which received the FDA Fast-Track designation and is in a
global Phase III clinical trial; (ii) Palupiprant (AN0025), an oral
EP4 antagonist which has completed Phase Ib trial in a neoadjuvant
setting in locally advanced rectal cancer and is undergoing Phase
1b trial in combination with Keytruda or pembrolizumab in patients
with multiple solid tumors; and (iii) AN4005, an oral small
molecule PD-L1 drug which is currently in Phase I trial that was
shown to functionally overcome the inhibition derived from PD-1/L1
interaction in reporter- and human PBMC-based cellular assays. In
addition, a Phase I clinical trial has been initiated for a
combination therapy consisting of AN2025, AN0025, and Tecentriq or
atezolizumab targeting a variety of PIK3CA mutant solid tumors.
Adlai Nortye has assembled an experienced
management team, built its unique immuno-oncology platforms and
partnered with multiple top pharmaceutical companies to promote
innovation. Adlai Nortye is committed to becoming an innovative
biopharmaceutical company with global vision and strives to benefit
patients worldwide. The ultimate goal of the Company is to
transform life-threating cancer into a chronic and eventually a
curable disease. For more information, please visit:
www.adlainortye.com.
About Nucleai:Nucleai is an
AI-driven biomarker and diagnostics company powered by digital
pathology and spatial biology. Leveraging all modalities of digital
pathology, Nucleai provides pharmaceutical companies, contract
research organizations, and diagnostics laboratories with a
state-of-the-art AI platform to improve clinical trials and
facilitate development/deployment of AI-powered diagnostics. For
more information, visit www.nucleai.ai.
Forward-Looking and Cautionary StatementsThis
announcement contains forward-looking statements. These statements
are made under the “safe harbor” provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements can be identified by terminology such as “will,”
“expects,” “anticipates,” “future,” “intends,” “plans,” “believes,”
“estimates,” “potential,” “continue,” “ongoing,” “targets” and
similar statements. Among other things, statements that are not
historical facts, including statements about the Company’s beliefs
and expectations, the business outlook and quotations from
management in this announcement, as well as the Company’s strategic
and operational plans, are or contain forward-looking
statements.
The Company may also make written or oral forward-looking
statements in its periodic reports to the U.S. Securities and
Exchange Commission (the “SEC”), in press releases and other
written materials and in oral statements made by its officers,
directors or employees to third parties. Forward-looking statements
involve inherent risks and uncertainties. Factors that could cause
the Company's actual results to differ materially from those
expressed or implied in such forward-looking statements include,
but are not limited to: the initiation, timing, progress and
results of the Company's preclinical studies, clinical trials and
other therapeutic candidate development efforts; the Company's
ability to advance its therapeutic candidates into clinical trials
or to successfully complete its preclinical studies or clinical
trials; whether the clinical trial results will be predictive of
real-world results; the Company's receipt of regulatory approvals
for its therapeutic candidates, and the timing of other regulatory
filings and approvals; the clinical development, commercialization
and market acceptance of the Company's therapeutic candidates; the
Company's ability to establish, manage, and maintain corporate
collaborations, as well as the ability of its collaborators to
execute on their development and commercialization plans; the
implementation of the Company‘s business model and strategic plans
for its business and therapeutic candidates; the scope of
protection the Company is able to establish and maintain for
intellectual property rights covering its therapeutic candidates
and its ability to operate its business without infringing the
intellectual property rights of others; estimates of the Company's
expenses, future revenues, capital requirements and its needs for
and ability to access sufficient additional financing; risks
related to changes in healthcare laws, rules and regulations in the
PRC and United States or elsewhere. Further information regarding
these and other risks is included in the Company’s filings with the
SEC. All information provided in this press release and in the
attachments is as of the date of this press release, and the
Company does not undertake any obligation to update any
forward-looking statement, except as required under applicable
law.
Contacts:Investor Relations:Charles ZhouAmanda
Kong
Adlai Nortye Ltd.ir@adlainortye.com
Adlai Nortye (NASDAQ:ANL)
過去 株価チャート
から 11 2024 まで 12 2024
Adlai Nortye (NASDAQ:ANL)
過去 株価チャート
から 12 2023 まで 12 2024